Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02352194
Other study ID # 14-REHABSEP
Secondary ID
Status Recruiting
Phase N/A
First received January 20, 2015
Last updated January 27, 2015
Start date July 2014
Est. completion date October 2015

Study information

Verified date May 2014
Source Assistance Publique - Hôpitaux de Paris
Contact Djamel Bensmail, MD, PhD
Phone +33147107060
Email djamel.bensmail@rpc.aphp.fr
Is FDA regulated No
Health authority France: Ministry of Health
Study type Observational

Clinical Trial Summary

The purpose of this study is to assess the physical capacity of patients with multiple sclerosis and the effects of rehabilitation, encompassing physical therapy and physical activity as it is carried out in the day hospital of (the Physical and Rehabilitation Medicine department) at Garches Hospital. We will compare the results of assessments carried out before and after a standard rehabilitation program.


Description:

Single center, retrospective and prospective study.

In order to assess the efficiency of the of usual rehabilitation proposed to patients in the day hospital, assessments are systematically performed before and after the rehabilitation program:

1. Assessment of muscular strength and fatigue:

Assessments of voluntary force will be those usually performed in the context of the evaluation of patients. The isokinetic dynamometer CON-TREX ® is a device that provides a quantified result of the torque developed in a predetermined joint area with a constant speed which is also defined in advance.

The assessment includes an assessment of the strength in isometric contraction (at 40 and 90 degrees of knee flexion) and concentric contraction (30, 60 and 90 degrees per second). Fatigue is evaluated by two self-administered questionnaires: the Fatigue Severity Scale and Modified Fatigue Impact Scale.

2. Effort test:

The aerobic capacity of patients will be assessed by a triangular maximal exercise test.

The effort test is performed on a cycle ergometer from a triangular incremental exercise. Beforehand, blood pressure and ECG are recorded to establish that the patient can safely achieve a gradual stress test. Heart rate, blood pressure, oxygen consumption, the feeling (Borg scale) and ECG are recorded immediately before and immediately after the end of the test and every minute for at least 5-10 minutes during the recovery phase.

3. Clinical assessment:

The Timed Up and Go test will be used to assess the patient's capacity of postural transition.

This is a timed quantitative assessment of the duration needed to change from sitting in a chair, get up and walk three meters, make a U-turn and come back to sit down.

The 10 meters test quantifies the walking speed of patients (meters / second) over 10 meters A test of ascending and descending10 stairs is also performed, as well as the 6 minutes walking test.

In addition to these functional assessments, clinical tests are conventionally performed such as the measurement of muscle strength (Medical Research Council scale), range of motion, spasticity (modified Ashworth scale) and an assessment of the balance and posture.

The SEP-59 questionnaire will be used to assess the patients quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Multiple Sclerosis with EDSS = 6 (Expanded Disability Status Scale)

- Patient = 18 years old

- Patient able to comply with the recommended monitoring

- No relapse within the last three months

- More than six months elapsed since last medical care in day hospital

- No recent modification (six month) of medications for MS

- More than three months elapsed since last change of associated treatments (Fampyra, botulinum toxin)

Exclusion Criteria:

- Patients under any form of guardianship or curatorship

- Breastfeeding

- Orthopedic complications with repercussions on walking activities

- No affiliation to a social security scheme (beneficiary or assignee)

Study Design

Observational Model: Cohort


Related Conditions & MeSH terms


Intervention

Other:
Rehabilitation
Physiotherapy and physical activity

Locations

Country Name City State
France Raymond Poincaré Hospital Garches

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of the strength and fatigue Assessment realised with an isokinetic dynamometer Within 10 weeks from the start of the rehabilitation program No
Secondary 6 minutes walking test Patients were instructed to walk as far as possible in a 50 meters corridor during 6 minutes Within 10 weeks from the start of the rehabilitation program No
Secondary Evaluation of aerobic capacity during an effort test Aerobic capacity (VO2max) Within 10 weeks from the start of the rehabilitation program No
Secondary Assessment of the balance of patients Berg Balance Scale Within 10 weeks from the start of the rehabilitation program No
Secondary Assessment of Spasticity with the Modified Ashworth Scale (MAS), Within 10 weeks from the start of the rehabilitation program No
Secondary 10 meters Walk test Patients have to walk over a 14 meter walkway and time required to traverse the middle 10 meters of the walk was recorded to avoid acceleration and deceleration effects Within 10 weeks from the start of the rehabilitation No
Secondary Timed up and go test Patients have to get up from a chair, walk 3 meters, turn around and return to sitting as quickly as possible Within 10 weeks from the start of the rehabilitation No
Secondary Time to ascend and descend stairs Participants were instructed to ascend and descend 10 stairs using the hand rail Within 10 weeks from the start of the rehabilitation No
Secondary Assessment of Strength with the Medical Research Council (MRC), Within 10 weeks from the start of the rehabilitation No
Secondary Assessment of Quality of Life with SEP-59 Scale Within 10 weeks from the start of the rehabilitation No
Secondary Assessment of the balance of patients Postural control assessment : eyes opened and eyes closed Within 10 weeks from the start of the rehabilitation No
See also
  Status Clinical Trial Phase
Recruiting NCT05177523 - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Not yet recruiting NCT06053749 - An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Not yet recruiting NCT06450600 - Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education N/A
Recruiting NCT04926818 - Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Phase 3
Not yet recruiting NCT03624296 - Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study N/A
Terminated NCT04203498 - Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis Phase 3
Active, not recruiting NCT04602390 - Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis Phase 1
Completed NCT01804647 - Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
Terminated NCT04907305 - Next-Gen MS: Feed-forward PRO Data for MS Research
Active, not recruiting NCT03456206 - Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Completed NCT04705610 - Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography N/A
Completed NCT01366027 - PRISM Registry: Pseudobulbar Affect Registry Series N/A
Completed NCT03135249 - Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis Phase 4
Recruiting NCT05633875 - Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
Completed NCT02612935 - An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis N/A
Completed NCT02739542 - Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) Phase 4
Completed NCT03177655 - Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis N/A
Active, not recruiting NCT04777539 - Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
Completed NCT02308579 - Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases N/A
Withdrawn NCT01710228 - Alternative Treatment Paradigm for Natalizumab Trial Phase 2